A woman in Nambour, Australia, is the first patient to receive a minimally invasive implantable neuromodulation device for severe migraine and cluster headache in a first-in-human study conducted by Salvia Bioelectronics BV.
/PRNewswire/ The neuromodulation market is projected to progress at a CAGR of 12.02 % between 2022 and 2027, the size of the market is forecast to increase.
Remote electrical neuromodulation treatment begins to prevent migraine attacks in as early as 2 weeks, as shown in a study that compared its effectiveness to placebo in warding off migraine.
Use of a remote electrical neuromodulation device every other day helped patients significantly reduce their number of migraine days compared with a placebo device, in new research.